These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471 [TBL] [Abstract][Full Text] [Related]
7. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033 [TBL] [Abstract][Full Text] [Related]
8. Conjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors. Dagi Glass LR; Lawrence DP; Jakobiec FA; Freitag SK Ophthalmic Plast Reconstr Surg; 2017; 33(5):e114-e116. PubMed ID: 27893585 [TBL] [Abstract][Full Text] [Related]
9. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667 [TBL] [Abstract][Full Text] [Related]
10. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer. Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307 [TBL] [Abstract][Full Text] [Related]
11. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma. Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202 [TBL] [Abstract][Full Text] [Related]
12. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Shi H; Kong X; Ribas A; Lo RS Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746 [TBL] [Abstract][Full Text] [Related]
13. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells. Lidsky M; Antoun G; Speicher P; Adams B; Turley R; Augustine C; Tyler D; Ali-Osman F J Biol Chem; 2014 Oct; 289(40):27714-26. PubMed ID: 25063807 [TBL] [Abstract][Full Text] [Related]
14. Unbiased Proteomic and Phosphoproteomic Analysis Identifies Response Signatures and Novel Susceptibilities After Combined MEK and mTOR Inhibition in BRAF Maxwell MJ; Arnold A; Sweeney H; Chen L; Lih TM; Schnaubelt M; Eberhart CG; Rubens JA; Zhang H; Clark DJ; Raabe EH Mol Cell Proteomics; 2021; 20():100123. PubMed ID: 34298159 [TBL] [Abstract][Full Text] [Related]
15. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer. Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606 [TBL] [Abstract][Full Text] [Related]
16. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Carlino MS; Todd JR; Gowrishankar K; Mijatov B; Pupo GM; Fung C; Snoyman S; Hersey P; Long GV; Kefford RF; Rizos H Mol Oncol; 2014 May; 8(3):544-54. PubMed ID: 24476679 [TBL] [Abstract][Full Text] [Related]
17. Spectrum and Frequency of BRAF Mutations in Skin Melanomas in the Dalmatian Region of Croatia. Bezić J; Tomić I; Pavić M Acta Dermatovenerol Croat; 2024 Mar; 32(1):75-76. PubMed ID: 38946192 [TBL] [Abstract][Full Text] [Related]
18. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Deng W; Gopal YN; Scott A; Chen G; Woodman SE; Davies MA Pigment Cell Melanoma Res; 2012 Mar; 25(2):248-58. PubMed ID: 22171948 [TBL] [Abstract][Full Text] [Related]
19. Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies. Wirtz ED; Hoshino D; Maldonado AT; Tyson DR; Weaver AM JAMA Otolaryngol Head Neck Surg; 2015 Jun; 141(6):543-9. PubMed ID: 25855885 [TBL] [Abstract][Full Text] [Related]
20. BRAF Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]